Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.

Abstract

Low serum albumin levels are very common in critically ill patients, with reported incidences as high as 40-50%. This condition appears to be associated with alterations in the degree of protein binding of many highly protein-bound antibacterials, which lead to altered pharmacokinetics and pharmacodynamics, although this topic is infrequently considered in daily clinical practice. The effects of hypoalbuminaemia on pharmacokinetics are driven by the decrease in the extent of antibacterial bound to albumin, which increases the unbound fraction of the drug. Unlike the fraction bound to plasma proteins, the unbound fraction is the only fraction available for distribution and clearance from the plasma (central compartment). Hence, hypoalbuminaemia is likely to increase the apparent total volume of distribution (V(d)) and clearance (CL) of a drug, which would translate to lower antibacterial exposures that might compromise the attainment of pharmacodynamic targets, especially for time-dependent antibacterials. The effect of hypoalbuminaemia on unbound concentrations is also likely to have an important impact on pharmacodynamics, but there is very little information available on this area. The objectives of this review were to identify the original research papers that report variations in the highly protein-bound antibacterial pharmacokinetics (mainly V(d) and CL) in critically ill patients with hypoalbuminaemia and without renal failure, and subsequently to interpret the consequences for antibacterial dosing. All relevant articles that described the pharmacokinetics and/or pharmacodynamics of highly protein-bound antibacterials in critically ill patients with hypoalbuminaemia and conserved renal function were reviewed. We found that decreases in the protein binding of antibacterials in the presence of hypoalbuminaemia are frequently observed in critically ill patients. For example, the V(d) and CL of ceftriaxone (85-95% protein binding) in hypoalbuminaemic critically ill patients were increased 2-fold. A similar phenomenon was reported with ertapenem (85-95% protein binding), which led to failure to attain pharmacodynamic targets (40% time for which the concentration of unbound [free] antibacterial was maintained above the minimal inhibitory concentration [fT>MIC] of the bacteria throughout the dosing interval). The V(d) and CL of other highly protein-bound antibacterials such as teicoplanin, aztreonam, fusidic acid or daptomycin among others were significantly increased in critically ill patients with hypoalbuminaemia compared with healthy subjects. Increased antibacterial V(d) appeared to be the most significant pharmacokinetic effect of decreased albumin binding, together with increased CL. These pharmacokinetic changes may result in decreased achievement of pharmacodynamic targets especially for time-dependent antibacterials, resulting in sub-optimal treatment. The effects on concentration-dependent antibacterial pharmacodynamics are more controversial due to the lack of data on this topic. In conclusion, altered antibacterial-albumin binding in the presence of hypoalbuminaemia is likely to produce significant variations in the pharmacokinetics of many highly protein-bound antibacterials. Dose adjustments of these antibacterials in critically ill patients with hypoalbuminaemia should be regarded as another step for antibacterial dosing optimization. Moreover, some of the new antibacterials in development exhibit a high level of protein binding although hypoalbuminaemia is rarely considered in clinical trials in critically ill patients. Further research that defines dosing regimens that account for such altered pharmacokinetics is recommended.

Overview

Integrity signals

Registry

Crossref · 10.2165/11539220-000000000-00000

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 60 references

Research works printed but not linked: 4

  1. Craig, 1978, Scand J Infect Dis Suppl, &NA;, 239
  2. Friend, 1997, Adv Perit Dial, 13, 155
  3. Goldstein, 1949, J Pharmacol Exp Ther, 95, 102
  4. Van Dalen, 1987, Pharm Weekbl Sci, 9, 98

Cited by

See all 469

Metadata

Authors
Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J.
Affiliations
  • The University of Queensland (AU)
  • Universitat Autònoma de Barcelona (ES)
Corresponding author
Roberts, Jason A.
Venue
Clinical Pharmacokinetics
Published
2011-02
Volume
50
Issue
2
Pages
99-110
ISSN
0312-5963 (ISSN-L)
OpenAlex
W1982910325
Cited by
469
References
60
Citations by year
2026: 32 · 2025: 44 · 2024: 38 · 2023: 40 · 2022: 47 · 2021: 39 · 2020: 44 · 2019: 26 · 2018: 17 · 2017: 24 · 2016: 23 · 2015: 28 · 2014: 21 · 2013: 15 · 2012: 23
FWCI
1.67
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Queensland Health
  • Australian and New Zealand College of Anaesthetists
  • Medical Research Council
  • National Health and Medical Research Council (519702)
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Keywords
hypoalbuminemia, critically ill patients, protein binding, drug-albumin binding, unbound drug fraction, volume of distribution, drug clearance, pharmacokinetics, pharmacodynamics, time above MIC, ceftriaxone, ertapenem, teicoplanin, aztreonam, fusidic acid, daptomycin
MeSH terms
Anti-Bacterial Agents, Clinical Trials as Topic, Humans, Kidney Function Tests, Microbial Sensitivity Tests, Protein Binding, Critical Illness, Hypoalbuminemia, Drug Dosage Calculations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. https://app.cochat.ai/papers/10.2165/11539220-000000000-00000
The paper
Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J. (2011). The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clinical Pharmacokinetics. https://doi.org/10.2165/11539220-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.